Intrauterine Contraceptive Devices Market Size, Share & Trends Analysis Report By Type (Hormonal Intrauterine Devices, Copper Intrauterine Devices), By Product (Mirena, Skyla, Paragard, Essure, Levosert, Others), By End-User (Hospitals, Gynecology Clinics, Community Healthcare Centers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global intrauterine contraceptive devices market size was valued at USD 2.89 billion in 2022. It is projected to reach USD 3.95 billion by 2031, growing at a CAGR of 3.5% during the forecast period (2023–2031).

An IUD is a small, T-shaped birth control device placed inside the uterus. When it comes to birth control, these methods are highly efficient, practical, and secure. The use of IUDs to avoid unwanted pregnancies is widely regarded as safe. IUDs work as contraceptives because they cause a small area of inflammation. Sperm are killed by chemicals released during the inflammatory response inside the uterus. It may have an impact on the sperm's ability to fertilize eggs. Even after an abortion, these are useful. One of the safest and most reliable birth control methods is an intrauterine device (IUD). Contraceptive IUDs are medical devices that a doctor or medical professional implants in the uterus. The duration of these varies from three years to ten years.

Market Dynamics

Market Drivers

Increase in Awareness of These Devices' Availability through Campaigns and Digital Advertisements

Intrauterine Devices (IUDs) are small T-shaped devices implanted in women's uteruses to prevent pregnancy. Copper IUDs and other hormonal contraceptives are widely used. The longevity, efficacy, convenience, and low cost of intrauterine contraceptive devices are just a few factors propelling the market. The demand in the market is heavily influenced by government initiatives that highlight the advantages of using IUDs. Spreading the word about these tools exists solely to feed the market demand, which is true even in developing nations. The market for intrauterine contraceptive devices is expanding rapidly due to both rising demand and the stimulating effect of constant innovation.

Market Restraints

High Cost of Device

One consideration in selecting a method of birth control is the available budget. An examination of the first-year costs for the various approaches reveals that they can be quite high and that there are significant variations between methods based on fees charged by private physicians and supplies purchased from pharmacies. The global market for intrauterine contraceptive devices may be slowed by factors such as heavy bleeding, irregular bleeding, and cramps. These are also the most common causes for removing an intrauterine device. In terms of preventing the spread of STDs, it is entirely ineffective.

Market Opportunity

Increasing Inclination towards Planned Delayed Pregnancy

Market expansion is anticipated to be fueled by rising demand from women who want to delay having children by choice. Increased interest in postponing pregnancy is predicted to result from the United States government's adoption of innovative strategies to expand access to sexual and reproductive health services and products. The fertility-preventing effectiveness of intrauterine devices is approximately 99% and lasts for 3-10 years. Teenage women are increasing in number across the country. With that comes a greater need for access to and use of contraceptives like intrauterine devices to prevent unsafe abortions and unintended pregnancies. It is adding to the already substantial product adoption to avoid unwanted pregnancies. Market opportunities for IUDs are expected to increase in the coming years due to the far-reaching consequences of unintended pregnancies.

Regional Analysis

The global intrauterine contraceptive devices market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

Europe Dominates the Global Market

Europe is the most significant shareholder in the global intrauterine contraceptive devices market and is expected to grow during the forecast period.  Due to its high adoption of IUDs over oral contraceptives, Europe is likely to dominate the market. Contraceptive IUDs are highly efficient and have fewer side effects overall. The European continent has the lowest fertility rate of any region on Earth. As a whole, the regional average is 1.44 children per family unit. To create new products with improved efficacy and fewer adverse side effects, manufacturers are pouring a lot of money and time into research and development (R&D). Rising healthcare costs and a growing preference among consumers for postponing having children are also expected to fuel demand.

Asia-Pacific is expected to grow during the forecast period. There are more unintended pregnancies in Asia and the Pacific, so it stands to reason that this region would also have a disproportionately large share of the market for intrauterine contraceptive devices. Increased healthcare-related government initiatives in Asia also contribute to the market's expansion. Intrauterine contraceptive device access has increased in recent years thanks to government and non-government organizations' efforts to reduce abortions and unwanted pregnancies.

The market for intrauterine contraceptive devices in North America is projected to become the world's second-largest. Women are increasingly aware of the problem, and IUDs are a permanent and highly effective solution. More and more women and doctors are becoming interested in UDs because they are one of the most effective forms of reversible contraception. Both hormone-free copper and hormone-based IUDs have seen the highest demand levels in the United States market. Mirena, Skyla, and Liletta are three of the most prevalent hormonal IUDs in the United States. New guidelines developed by the American College of Obstetricians and Gynecologists have increased the use of IUDs among patients.

A lack of awareness and unmet demands will likely limit growth in LAMEA. According to the UN report, 24 percent of the unmet need was in sub-Saharan Africa. Where contraceptive use is uncommon, the unmet need tends to be high. Moreover, contraceptive use was relatively high in most Latin American and Caribbean nations. Intrauterine devices have seen increased uptake due to their many advantages, including their ability to prevent pregnancy over the long term, their reduced impact on fertility, their reduced severity of menstruation, and their status as a highly effective method of contraception.

Segmental Analysis

The global intrauterine contraceptive devices market is segmented by type, product, and end-user.

By Type Analysis

Based on type, the global intrauterine contraceptive devices market is bifurcated into hormonal intrauterine devices and copper intrauterine devices.

The hormonal intrauterine devices segment is the highest contributor to the market and is expected to grow during the forecast period. It’s because hormonal intrauterine devices provide several benefits to women's health. These intrauterine devices (IUDs) are one of the most effective forms of contraception, with a success rate of nearly 99% in preventing pregnancies. It helps with various things, including long-term contraception, reduced risk of pelvic infections, reduced menstrual flow, and pain-free periods. Healthcare providers advocate for hormonal IUDs for their many advantages and improved patient outcomes. Patients with heavy menstrual bleeding, endometriosis, anemia, fibroids, etc., can use hormonal IUDs because they are very safe because of their non-contraceptive benefits. Hormonal IUDs effectively prevent pregnancy by thinning the uterus lining, partially suppressing ovulation, and thickening the cervix's mucus. As a result, the many benefits that hormonal IUDs provide are likely to increase their popularity and the industry's bottom line in the coming years.

By Product Analysis

Based on product, the global intrauterine contraceptive devices market is bifurcated into Mirena, Skyla, paragard, essure, levosert, and others.

The Mirena segment is the highest contributor to the market and is expected to grow during the forecast period. Mirena is an IUD that releases hormones into the uterus and can be used as a method of permanent contraception. After insertion, Mirena can effectively prevent pregnancy for up to seven years. Several hormonal IUDs have received FDA clearance. After three months of use, Mirena has significantly reduced menstrual bleeding. After one year of using Mirena, about 20% of women report they no longer have periods. Mirena has a seven-year lifespan once implanted. As a result, the many benefits that hormonal IUDs provide are likely to increase their popularity and the industry's bottom line in the coming years.

By End-User Analysis

Based on end-user, the global intrauterine contraceptive devices market is bifurcated into hospitals, gynecology clinics, and community healthcare centers.

The hospital segment is the highest contributor to the market and is expected to grow during the forecast period. A rise in preventative healthcare visits combined with better hospital facilities in developing nations could lead to a sizable market share for hospitals. The client's background, medical eligibility, and the context of the health worker all play a role in shaping the health worker's values and preferences regarding contraception. Harmful bias toward specific populations or certain methods can negatively impact patient-centered care, including the provision of contraception. Improving and standardizing education and training globally to address knowledge gaps and health worker biases is necessary to guarantee future high-quality, rights-based, patient-centered contraceptive services.

Recent Developments

• October 2022- Global Blood Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development, and delivery of life-changing treatments for underserved patient communities, beginning with those suffering from sickle cell disease, has been acquired by Pfizer Inc.
• June 2021- Phase III clinical trial evaluating the efficacy, safety, and tolerability of LevoCept, a long-acting reversible intrauterine system, is being conducted by Sebela Pharmaceuticals Inc. in conjunction with PRA Health Sciences.